Alpha DNA Investment Management’s Progressive PGR Stock Holding History

Alpha DNA Investment Management’s Portfolio PGR Stock Details PGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,241	Closed	-$822K	–	246
2024 Q3	$822K	Buy	+3,241	New	+$754K	0.31%	71
2024 Q1	–	Sell	-5,139	Closed	-$819K	–	235
2023 Q4	$819K	Buy	+5,139	New	+$805K	0.32%	60

Other funds holding PGR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Alpha DNA Investment Management's PGR Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of Progressive (PGR) in Q4 2024, closing a stake of 3,241 shares — an estimated $822K sold.

Alpha DNA Investment Management first reported a position in PGR in Q4 2023 and held it in 2 quarters. The position peaked at $822K in Q3 2024. 1,761 funds tracked by Wall St. Rank hold PGR as of Q4 2024.

Alpha DNA Investment Management reported no remaining Progressive position as of Q4 2024 after selling out during the quarter.
Alpha DNA Investment Management sold 3,241 Progressive shares in Q4 2024, an estimated $822K.
Alpha DNA Investment Management first reported a position in Progressive in Q4 2023 and held it in 2 quarters.
Alpha DNA Investment Management's Progressive position peaked at $822K in Q3 2024.
1,761 funds tracked by Wall St. Rank held Progressive as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.